- Home
- RXRX vs AKRO Comparison
RXRX vs AKRO Comparison
Compare RXRX & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- AKRO
- Stock Information
- Founded
- RXRX 2013
- AKRO 2017
- Country
- RXRX United States
- AKRO United States
- Employees
- RXRX N/A
- AKRO N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- RXRX Health Care
- AKRO Health Care
- Exchange
- RXRX Nasdaq
- AKRO Nasdaq
- Market Cap
- RXRX 2.6B
- AKRO 2.2B
- IPO Year
- RXRX 2021
- AKRO 2019
- Fundamental
- Price
- RXRX $6.90
- AKRO $28.36
- Analyst Decision
- RXRX Buy
- AKRO Strong Buy
- Analyst Count
- RXRX 5
- AKRO 8
- Target Price
- RXRX $9.25
- AKRO $46.83
- AVG Volume (30 Days)
- RXRX 15.4M
- AKRO 535.2K
- Earning Date
- RXRX 11-06-2024
- AKRO 11-08-2024
- Dividend Yield
- RXRX N/A
- AKRO N/A
- EPS Growth
- RXRX N/A
- AKRO N/A
- EPS
- RXRX N/A
- AKRO N/A
- Revenue
- RXRX $65,184,000.00
- AKRO N/A
- Revenue This Year
- RXRX $60.17
- AKRO N/A
- Revenue Next Year
- RXRX $19.88
- AKRO N/A
- P/E Ratio
- RXRX N/A
- AKRO N/A
- Revenue Growth
- RXRX 37.64
- AKRO N/A
- 52 Week Low
- RXRX $5.60
- AKRO $15.32
- 52 Week High
- RXRX $15.74
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- RXRX 49.29
- AKRO 46.87
- Support Level
- RXRX $6.75
- AKRO $28.45
- Resistance Level
- RXRX $7.85
- AKRO $31.41
- Average True Range (ATR)
- RXRX 0.73
- AKRO 1.29
- MACD
- RXRX -0.02
- AKRO -0.15
- Stochastic Oscillator
- RXRX 15.43
- AKRO 37.64
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.